Market Overview

Analyst Says Inogen Won't Restate Prior Results


Inogen Incm (NASDAQ: INGN) won't need to restate revenue when it reports delayed results for its 2014 fourth quarter, an analyst said Thursday.

Inogen changed hands recently at $36.71, up 3.8 percent. Shares are up more than 16 percent year-to-date.

Needham's Michael Matson reinstated coverage of the health care company with a Strong Buy rating and $45 target.

Matson had worried that a downward restatement of previous results would produce a slower-than-expected growth rate.

The company, which provides portable oxygen units for home health care, said earlier this week that its direct-to-consumer sales representatives violated company policy with "modified documentation."

The accounting issue won't result in a restatement, the company said. On April 1, the company had announced the reporting delay, but didn't offer details.

Matson expects the company will beat expectations for the fourth quarter.

The company's forecasts "appear to imply a significant slowdown that "doesn't seem justified in light of their recent performance," Matson said.

The company, which went pubic in February 2014 at $16 a share, offers a non-transferable warranty via direct-to-consumer sales that provides a functional oxygen concentrator for the lifetime of a patient.

Inogen estimates that on average, all of its customers will succumb to their disease within five years.

Direct-to-consumer sales and rentals represented about 58 percent of the company's revenue for the three months ended September 2014.

Latest Ratings for INGN

Nov 2019UpgradesHoldBuy
Aug 2019DowngradesOutperformMarket Perform
Aug 2019DowngradesBuyHold

View More Analyst Ratings for INGN
View the Latest Analyst Ratings

Posted-In: Michael Matson NeedhamAnalyst Color Health Care Price Target Reiteration Analyst Ratings General


Related Articles (INGN)

View Comments and Join the Discussion!

Latest Ratings

AMRXRaymond JamesDowngrades
CATStandpoint ResearchDowngrades
LULUWells FargoMaintains260.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Filing from EMC Corp. Shows Proxy Materials in Letter to Holders from Non-Mgmt Members of Co. Board

8 Managed Care Stocks To Watch In Earnings Season